, Tracking Stock Market Picks
Enter Symbol:
Mannkind Corporation (MNKD) [hlAlert]

up 99.74 %

Mannkind Corporation (MNKD) downgraded to Underperform with price target $5 by Leerink Swann

Posted on: Tuesday,  Jul 14, 2009  8:25 AM ET by Leerink Swann

Leerink Swann rated Underperform Mannkind Corporation (NASDAQ: MNKD) on 07/14/2009, when the stock price was $7.81. Since
then, Mannkind Corporation has lost 49.94% as of 01/06/2016's recent price of $3.91.
If you would have followed this Leerink Swann 's recommendation on MNKD, you would have gained 99.74% of your investment in 2367 days.

Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/14/2009 8:25 AM Sell
7.81 5.00
as of 12/31/2009
1 Week up  34.91 %
1 Month up  20.66 %
3 Months up  41.52 %
1 YTD up  26.24 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/9/2008 12:25 PM Hold

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy